LHCCX Mutual Fund

NAV$22.21

Fund Essentials - as of Jan 31, 2026

Net Assets
-
Expense Ratio
1.78%
Dividend Yield (Current)
-
Holdings
61
Inception Date
Jul 31, 2019
Fund Family
Lord Abbett Family of Funds
Investment Style
••••••••••
Asset Class
••••••••••
Legal Structure
••••••••••
Dividend Frequency
Annually

Performance

YTD+3.49%
1 Year+26.33%
3 Year+8.30%
5 Year+4.86%

Asset Allocation

Stocks: 95.05%
Cash: 0.76%
Other: 4.19%

Price Chart (6M)

View Full Chart →

Top Holdings

View All →
TickerNameWeight
LLYEli Lilly & Co9.24%
GILDGilead Sciences Inc4.32%
-Sold GBP Bought USD 202510024.13%
AZN:LNAstraZeneca PLC3.96%
0QW0:ASargenx SE3.86%
Top 10 Concentration: 40.14%Report Date: Jan 31, 2026
Download all 61 holdings for LHCCX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Frequency
Annually
Latest Distribution
$1.47
-

Peer Comparison

Benchmark
••••••••••
Outperforming by ••••%
Ranked #••• of •,••• funds
This Mutual Fund
+••.••%
Peer Avg
+••.••%
Premium Feature
Sign in to unlock peer comparison, category rankings and more

LHCCX Mutual Fund Overview

LHCCX Mutual Fund (Lord Abbett Health Care Fund) is managed by Lord Abbett Family of Funds. LHCCX expense ratio is 1.78%, holding 61 positions across sectors including Health Care, Unknown, Other. Inception date: 2019-07-31.

LHCCX performance shows a YTD return of 3.49%. The 1-year return is 26.33% and the 5-year return is 4.86%.

LHCCX top holdings include Eli Lilly & Co (9.2%), Gilead Sciences Inc (4.3%), Sold GBP Bought USD 20251002 (4.1%), AstraZeneca PLC (4.0%), argenx SE (3.9%). View all LHCCX holdings, sector breakdown, or dividend history.

LHCCX can be compared against other funds using the overlap calculator or side-by-side comparison tool. LHCCX alternatives are available via the screener, along with tax-loss harvesting opportunities.